Radiopharm Theranostics Limited American Depositary Shares (RADX) - Total Liabilities
Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has total liabilities worth $41.19 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Radiopharm Theranostics Limited American to track the company's year-over-year net asset growth rate.
Radiopharm Theranostics Limited American Depositary Shares - Total Liabilities Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Medipharm Labs Corp
TO:LABS
|
Canada | CA$8.52 Million |
|
The Peria Karamalai Tea & Produce Company Limited
NSE:PKTEA
|
India | Rs1.46 Billion |
|
Sungmoon Elect
KO:014910
|
Korea | ₩39.29 Billion |
|
Ever Shine Textile Industry
JK:ESTI
|
Indonesia | Rp504.43 Billion |
|
Q/C Technologies, Inc.
NASDAQ:QCLS
|
USA | $14.60 Million |
|
Aurora Mobile Ltd
NASDAQ:JG
|
USA | $316.94 Million |
|
Klaria Pharma Holding AB
ST:KLAR
|
Sweden | Skr50.62 Million |
|
Seojin Automotive Co.Ltd
KQ:122690
|
Korea | ₩1.62 Trillion |
Liability Composition Analysis (2022–2025)
This chart breaks down Radiopharm Theranostics Limited American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RADX market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Radiopharm Theranostics Limited American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
The table below shows the annual total liabilities of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $43.61 Million | -2.40% |
| 2024-06-30 | $44.68 Million | +52.14% |
| 2023-06-30 | $29.37 Million | +43.84% |
| 2022-06-30 | $20.42 Million | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more